Skip to content
Advertisement

In this image provided by the Serum Institute of India, vials of freshly manufactured Novavax COVID-19 vaccines wait to be labeled in 2022, in Pune, India. The U.S. Food and Drug Administration is evaluating a more traditional kind of vaccine made by Novavax, which the company hopes can win over unvaccinated people and become a top choice for boosters. (Serum Institute of India for Novavax via AP)

In this image provided by the Serum Institute of India, vials of freshly manufactured Novavax COVID-19 vaccines wait to be labeled in 2022, in Pune, India. The U.S. Food and Drug Administration is evaluating a more traditional kind of vaccine made by Novavax, which the company hopes can win over unvaccinated people and become a top choice for boosters. (Serum Institute of India for Novavax via AP)

Featured Photo Galleries